Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study

MLA

Eytan M. Stein, et al. “Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.” Clinical Lymphoma Myeloma and Leukemia, vol. 19, Sept. 2019, p. S220. EBSCOhost, https://doi.org/10.1016/j.clml.2019.07.094.

APA

Eytan M. Stein, Martha Arellano, Martin S. Tallman, Alice S. Mims, Bin Fan, Justin M. Watts, Denice Hickman, Stephanie M. Kapsalis, Courtney D. DiNardo, Richard Stone, Will Donnellan, Katharine E. Yen, Stéphane de Botton, David Dai, Sung Choe, Gabriel N. Mannis, Eyal C. Attar, Vickie Zhang, Hagop M. Kantarjian, … Jessica K. Altman. (2019). Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study. Clinical Lymphoma Myeloma and Leukemia, 19, S220. https://doi.org/10.1016/j.clml.2019.07.094

Chicago

Eytan M. Stein, Martha Arellano, Martin S. Tallman, Alice S. Mims, Bin Fan, Justin M. Watts, Denice Hickman, et al. 2019. “Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.” Clinical Lymphoma Myeloma and Leukemia 19 (September): S220. doi:10.1016/j.clml.2019.07.094.